Completed PHASE2 INTERVENTIONAL 4-arm NCT05669599

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Sponsor: Amgen

Conditions Obesity Overweight Type 2 Diabetes Mellitus

Interventions Maridebart Cafraglutide Placebo

Updated 21 times since 2023 Last updated: Jan 14, 2026 Started: Jan 18, 2023 Primary completion: Oct 8, 2024 Completion: Dec 16, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Obesity and Overweight, this trial is completed. The trial is conducted by Amgen and has accumulated 21 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

21 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE2
Feb 2026 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2026 — Present [monthly]

Active Not Recruiting PHASE2
Dec 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 16 earlier versions

Mar 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE2
Dec 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE2

First recorded

Jan 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Adelaide, Australia , Aki-gun, Japan , Beavercreek, United States , Berlin, Germany , Brampton, Canada , Brownsville, United States , Budapest, Hungary , Bydgoszcz, Poland , Calgary, Canada and 56 more locations